Transcatheter Aortic Valve Implantation to Treat Degenerated Aortic, Mitral and Tricuspid Bioprosthesis DOI Open Access
Arif Khokhar, Jonathan Curio, Alessandro Sticchi

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(2), P. 592 - 592

Published: Jan. 19, 2024

Transcatheter aortic valve implantation (TAVI) is now well established as the treatment of choice for patients with native stenosis who are high or intermediate risk surgical replacement. Recent data has also supported use TAVI in at low and anatomical subsets that were previously felt to be contra-indicated including bicuspid valves regurgitation. With advancements refinements procedural techniques, application this technology been further expanded include management degenerated bioprosthesis. After demonstration feasibility safety bioprosthetic valves, mitral tricuspid well-established provides an attractive alternative performing redo surgery. In review, we appraise latest clinical evidence highlight considerations when utilising aortic, prosthesis.

Language: Английский

Hemolytic Anemia Following SAPIEN 3 Ultra RESILIA Implantation (From the OCEAN-TAVI Registry) DOI
Kenichi Ishizu, Shinichi Shirai, Masaomi Hayashi

et al.

The American Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
Transcatheter heart valve explantation for transcatheter aortic valve replacement failure: A Heart Valve Collaboratory expert consensus document on operative techniques DOI Creative Commons
Tsuyoshi Kaneko,

Vinayak N Bapat,

Ali M Alakhtar

et al.

Journal of Thoracic and Cardiovascular Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: April 1, 2024

Language: Английский

Citations

8
Deformation in transcatheter heart valves: Clinical implications and considerations DOI
Miho Fukui, João L. Cavalcante, Vinayak Bapat

et al.

Journal of Cardiology, Journal Year: 2024, Volume and Issue: 83(6), P. 351 - 358

Published: March 1, 2024

Language: Английский

Citations

4
Lifetime Management in Aortic Valve Disease DOI Creative Commons
Miho Fukui

JACC Case Reports, Journal Year: 2025, Volume and Issue: unknown, P. 103310 - 103310

Published: Jan. 1, 2025

Language: Английский

Citations

0
Risk of coronary obstruction and protection strategies in transcatheter aortic valve implantation DOI Creative Commons
Yafeng Peng,

Ruqiong Nie,

Haifeng Zhang

et al.

Journal of Zhejiang University (Medical Sciences), Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Transcatheter aortic valve replacement (TAVR) has emerged as the first-line treatment for stenosis. Coronary obstruction is a severe complication of TAVR, with mortality rates exceeding 30%. can be classified acute or delayed based on timing onset, and direct indirect according to underlying mechanism. Risk factors predicting coronary include small sinus Valsalva diameter, excessively long native leaflets, low height, sinotubular junction height diameter. Accurate preoperative assessment these anatomical parameters using CT crucial selecting appropriate type, size, implantation depth. Preventive technical strategies intraoperative interventional treatments (such "Chimney" stenting technique), leaflet modification BASILICA alignment annulus coronaries. These techniques have demonstrated significant efficacy in reducing incidence associated mortality. This paper reviews epidemiology, classification, mechanisms obstruction, particular focus identification, prevention, high-risk patients. The aim highlight importance recognizing managing risks during TAVR provide actionable recommendations prevention clinical practice.

Language: Английский

Citations

0
In Vivo Computed Tomography Sizing for Redo–Transcatheter Aortic Valve Replacement in Evolut Valves: Impact on Sizing, Feasibility, and Prosthesis-Patient Mismatch DOI
Atsushi Okada, Miho Fukui, Syed Zaid

et al.

Circulation Cardiovascular Interventions, Journal Year: 2024, Volume and Issue: 17(8)

Published: Aug. 1, 2024

SAPIEN3 (S3) is a ubiquitous redo-transcatheter aortic valve (TAV) replacement alternative for degenerated Evolut valves, but S3 sizing S3-in-Evolut remains unclear. We sought to compare the impact of in vivo computed tomography (CT)-sizing on redo-TAV feasibility with traditional bench-sizing.

Language: Английский

Citations

1
Lifetime management considerations to optimise transcatheter aortic valve implantation: a practical guide DOI

K. Rao,

Alexandra Baer, Vinayak Bapat

et al.

EuroIntervention, Journal Year: 2024, Volume and Issue: 20(24), P. e1493 - e1504

Published: Dec. 1, 2024

Transcatheter aortic valve implantation (TAVI) is a safe and effective procedure for the treatment of stenosis. With recently broadened indications, there larger cohort patients likely to outlive their first transcatheter heart (THV). This review discusses relevant lifetime planning considerations, focusing on utility preprocedural computed tomography imaging help implanters future-proof who are valve. The initial priority optimise index by maximising THV haemodynamic function durability. involves orifice area, minimising risk new pacemaker implantation, reducing paravalvular regurgitation, preventing coronary obstruction annular rupture. In requiring second procedure, significant proportion will require TAVI-in-TAVI, should consider key priorities redo including increased risks patient-prosthesis mismatch conduction abnormalities, promoting reaccessibility, sinus sequestration. Careful can identify potential hurdles as well predict feasibility outcomes redo-TAVI, individualise care over each patient.

Language: Английский

Citations

1
Optimizing Valve Selection in Valve-in-Valve Transcatheter Aortic Valve Replacement: A Case Study on Addressing Patient-Prosthesis Mismatch and Early Structural Valve Deterioration in a Morbidly Obese Patient DOI Open Access

Victor H Molina-Lopez,

Ismael Ortiz-Cartagena,

Josué Mercado-Crespo

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 29, 2024

Transcatheter aortic valve replacement (TAVR) has increasingly become a fundamental approach for treating stenosis (AVS), especially in high surgical risk patients. This case study underscores the criticality of meticulous procedural planning and precise selection patients with severe AVS compounded by obesity. We report patient who, after receiving 26 mm Edwards Sapiens 3 valve, presented worsening exertional dyspnea declining indexed effective orifice area (EOAi). deterioration indicated early structural (SVD), presumably due to patient-prosthesis mismatch (PPM). A subsequent valve-in-valve (ViV) TAVR using 29 Medtronic Evolut Fx was successfully executed, leading notable improvement EOAi. emphasizes complexities inherent choice sizing TAVR, particularly highlighting impact PPM on obese its potential precipitate SVD. The further explores emerging strategies addressing dysfunctions via ViV interventions, shedding light nuanced dynamic nature management It advocates tailored treatment managing such intricate cases, demonstrating evolving landscape procedures.

Language: Английский

Citations

0
Redo-TAVI with the SAPIEN 3 valve in degenerated calcified CoreValve/Evolut explants DOI
David S. Meier,

Anish Nigade,

Althea Lai

et al.

EuroIntervention, Journal Year: 2024, Volume and Issue: 20(22), P. 1390 - 1404

Published: Nov. 1, 2024

Redo-transcatheter aortic valve implantation (TAVI) is the treatment of choice for failed transcatheter valves. Currently, a SAPIEN 3 (S3) indicated redo-TAVI in degenerated CoreValve/Evolut (CV/EV) valves (TAVs) but not well understood.

Language: Английский

Citations

0
Balloon Aortic Valvuloplasty with Simultaneous Aortic Root Injection: A case report of an Adjunctive Strategy to Computed Tomography for Predicting Coronary Obstruction in transcatheter aortic valve-in-transcatheter aortic valve (TAV-in-TAV) Procedures DOI Creative Commons

Tetsuro Shimura,

Masanori Yamamoto,

Hitoshi Matsuo

et al.

European Heart Journal - Case Reports, Journal Year: 2024, Volume and Issue: 8(12)

Published: Nov. 26, 2024

Computed tomography (CT) assessment is the standard for predicting coronary obstruction (CO) caused by sinus sequestration (SS) during transcatheter aortic valve (TAV) implantation in degenerated TAV (TAV-in-TAV) procedure, but it may not always be accurate. This report describes a prediction method CO using balloon valvuloplasty (BAV) TAV-in-TAV.

Language: Английский

Citations

0